{
 "metadata": {
  "name": "",
  "signature": "sha256:3b350b831cde74d7678925fe211a34daa6490ea09f69c94e3bb0afe5491e6a92"
 },
 "nbformat": 3,
 "nbformat_minor": 0,
 "worksheets": [
  {
   "cells": [
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "import csv\n",
      "\n",
      "\n",
      "start_string = \"Processing text_000N_19940\"\n",
      "\n",
      "path = \"/Users/phuong/Downloads/MetaMap_Results_TitlesOnly.txt\"\n",
      "drug_entities_dict = {}\n",
      "count = 0\n",
      "with open(path, 'r') as f:\n",
      "    for line in f:\n",
      "        line = line.replace(\"\\n\", \"\")\n",
      "        if start_string in line:\n",
      "            count = count + 1\n",
      "            string = 'tx.' + str(count) + \": \"\n",
      "            title = line.split(string)[1]\n",
      "            title = title.lstrip()\n",
      "            title = title.rstrip()\n",
      "            print title\n",
      "            drug_entities_dict[title] = []\n",
      "            continue\n",
      "        if \"Pharmacologic Substance\" in line:\n",
      "            drug_entities_dict[title].append(line)\n",
      "print len(drug_entities_dict)\n",
      "\n",
      "drug_entities_articles_dict = {}\n",
      "drug_entities_list = []\n",
      "for key,values in drug_entities_dict.items():\n",
      "    drug_entities_articles_dict[key] = []\n",
      "    for value in values:\n",
      "        value = ''.join([i for i in value if not i.isdigit()])\n",
      "        value = value.lstrip()\n",
      "        value = value.split(\" \")\n",
      "        substance = value[0]\n",
      "        substance = substance.lower()\n",
      "        substance = substance.rstrip()\n",
      "        substance = substance.replace(\",\",\"\")\n",
      "        if substance not in drug_entities_articles_dict[key]:\n",
      "            drug_entities_articles_dict[key].append(substance)\n",
      "        if substance not in drug_entities_list:\n",
      "            drug_entities_list.append(substance)\n",
      "\n",
      "feature_output = {}\n",
      "for key,values in drug_entities_articles_dict.items():\n",
      "    feature_output[key] = {}\n",
      "    for drug in drug_entities_list:\n",
      "        if drug in values:\n",
      "            feature_output[key][drug] = '1'\n",
      "        else:\n",
      "            feature_output[key][drug] = '0'\n",
      "\n",
      "import pandas as pd\n",
      "\n",
      "df = pd.DataFrame.from_dict(feature_output)\n",
      "# df.transpose()\n",
      "# print df\n",
      "df.to_csv('/Users/phuong/Downloads/dict.csv')\n",
      "\n",
      "        \n",
      "\n",
      "\n",
      "\n",
      "            \n",
      "            \n",
      "\n",
      "\n",
      "                  "
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.\n",
        "Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A.\n",
        "Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.\n",
        "The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin.\n",
        "Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects.\n",
        "Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.\n",
        "Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.\n",
        "Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.\n",
        "Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.\n",
        "Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.\n",
        "Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers.\n",
        "Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.\n",
        "Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects.\n",
        "The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.\n",
        "Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.\n",
        "Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics.\n",
        "A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.\n",
        "Lack of interaction between ramipril and simvastatin.\n",
        "Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol.\n",
        "Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects.\n",
        "The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy.\n",
        "Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.\n",
        "Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.\n",
        "Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.\n",
        "Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.\n",
        "A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers.\n",
        "Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.\n",
        "Carbamazepine but not valproate induces bupropion metabolism.\n",
        "Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.\n",
        "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.\n",
        "The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.\n",
        "Cimetidine interaction with amitriptyline.\n",
        "Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine.\n",
        "Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men.\n",
        "The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.\n",
        "Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.\n",
        "Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.\n",
        "Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.\n",
        "Coadministration of short-term zolpidem with sertraline in healthy women.\n",
        "Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.\n",
        "Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.\n",
        "Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.\n",
        "An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.\n",
        "Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem.\n",
        "Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole.\n",
        "Diltiazem enhances the effects of triazolam by inhibiting its metabolism.\n",
        "Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.\n",
        "The effect of fluconazole on the pharmacokinetics of rosuvastatin.\n",
        "The interaction of diltiazem with lovastatin and pravastatin.\n",
        "Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects.\n",
        "The effect of ranitidine and cimetidine on imipramine disposition.\n",
        "Cimetidine interaction with imipramine and nortriptyline.\n",
        "Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability.\n",
        "The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects.\n",
        "Pharmacokinetics of mirtazapine and lithium in healthy male subjects.\n",
        "Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers.\n",
        "A potentially hazardous interaction between erythromycin and midazolam.\n",
        "Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects.\n",
        "Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.\n",
        "Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.\n",
        "Effect of itraconazole on the pharmacokinetics of atorvastatin.\n",
        "Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam.\n",
        "Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers.\n",
        "Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.\n",
        "Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram.\n",
        "Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans.\n",
        "Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.\n",
        "Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.\n",
        "Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole.\n",
        "Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.\n",
        "Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.\n",
        "Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem.\n",
        "Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.\n",
        "Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.\n",
        "Effect of itraconazole on the pharmacokinetics of rosuvastatin.\n",
        "Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies.\n",
        "Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.\n",
        "Dose of midazolam should be reduced during diltiazem and verapamil treatments.\n",
        "Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.\n",
        "The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.\n",
        "Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam.\n",
        "In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.\n",
        "Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.\n",
        "Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects.\n",
        "Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.\n",
        "The effect of erythromycin on the pharmacokinetics of rosuvastatin.\n",
        "Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.\n",
        "The effect of ingestion time interval on the interaction between itraconazole and triazolam.\n",
        "A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.\n",
        "Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.\n",
        "Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.\n",
        "Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.\n",
        "Lack of interaction between citalopram and the CYP3A4 substrate triazolam.\n",
        "Inhibition of CYP2D6 activity by bupropion.\n",
        "The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.\n",
        "The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.\n",
        "The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.\n",
        "Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.\n",
        "Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.\n",
        "Paroxetine shifts imipramine metabolism.\n",
        "Effect of venlafaxine on imipramine metabolism.\n",
        "Effect of alosetron on the pharmacokinetics of fluoxetine.\n",
        "Dose-related reduction in bupropion plasma concentrations by ritonavir.\n",
        "Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.\n",
        "Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).\n",
        "Erythromycin coadministration increases plasma atorvastatin concentrations.\n",
        "Influence of fluoxetine on olanzapine pharmacokinetics.\n",
        "The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid.\n",
        "Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.\n",
        "Comparison of midazolam and simvastatin as cytochrome P450 3A probes.\n",
        "Pharmacokinetics of aripiprazole and concomitant lithium and valproate.\n",
        "Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline.\n",
        "Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.\n",
        "Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.\n",
        "The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.\n",
        "Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.\n",
        "The interaction of diltiazem with simvastatin.\n",
        "The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine.\n",
        "Effect of fluvoxamine on the pharmacokinetics of quinidine.\n",
        "Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.\n",
        "Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.\n",
        "In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.\n",
        "In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine.\n",
        "Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine.\n",
        "The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders.\n",
        "Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia.\n",
        "Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.\n",
        "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\n",
        "Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.\n",
        "Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.\n",
        "Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.\n",
        "The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite.\n",
        "Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.\n",
        "Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.\n",
        "Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.\n",
        "Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers.\n",
        "The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.\n",
        "Warfarin-fluconazole.\n",
        "II.\n",
        "A metabolically based drug interaction: in vivo studies.\n",
        "Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.\n",
        "Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.\n",
        "The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam.\n",
        "Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.\n",
        "Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.\n",
        "Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.\n",
        "Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite.\n",
        "Absolute bioavailability of clarithromycin after oral administration in humans.\n",
        "The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses.\n",
        "Pharmacokinetics of chlorpromazine and key metabolites.\n",
        "Pharmacokinetics of diltiazem after intravenous and oral administration.\n",
        "Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.\n",
        "Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin.\n",
        "Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial.\n",
        "Clarithromycin pharmacokinetics in healthy young and elderly volunteers.\n",
        "Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics.\n",
        "Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial.\n",
        "Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.\n",
        "The pharmacokinetics of ketoconazole after chronic administration in adults.\n",
        "Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.\n",
        "Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers.\n",
        "Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose.\n",
        "Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.\n",
        "Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers.\n",
        "Disposition and biotransformation of the antipsychotic agent olanzapine in humans.\n",
        "Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers.\n",
        "Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.\n",
        "CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.\n",
        "The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin.\n",
        "Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.\n",
        "Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.\n",
        "Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.\n",
        "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.\n",
        "Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion.\n",
        "Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans.\n",
        "Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.\n",
        "Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects.\n",
        "Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype.\n",
        "Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.\n",
        "CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.\n",
        "Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism.\n",
        "Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.\n",
        "Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.\n",
        "Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.\n",
        "SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.\n",
        "Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.\n",
        "Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.\n",
        "SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.\n",
        "The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.\n",
        "186\n"
       ]
      }
     ],
     "prompt_number": 56
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 61
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [],
     "language": "python",
     "metadata": {},
     "outputs": []
    }
   ],
   "metadata": {}
  }
 ]
}